Joshua Cohen is an independent healthcare analyst. He specializes in healthcare policy, drug pricing, and reimbursement, with a keen interest in the intersection of medicine and society. His insights and analyses have been featured in prominent publications such as Salon Media Group, Inc., Forbes, The New Yorker, and Undark Magazine.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Joshua Cohen's focus is predominantly on the healthcare and pharmaceutical industry, particularly with an emphasis on legal policy regulations and government announcements. His articles often cite data to support his coverage.
When reaching out to Joshua, consider providing insights from experts in the healthcare sector who can offer data-driven analysis or commentary related to drug pricing, public health policies, or regulatory changes within the industry. Additionally, pitches addressing significant government announcements impacting healthcare and pharmaceuticals may align well with his coverage preferences.
While not explicitly stated, it’s clear that Joshua has a keen interest in YouTube channels as per one of his article titles. If you have relevant insights into this aspect of media consumption that intersects with healthcare topics covered by him, it might be worth incorporating such angles into your pitches.
This information evolves through artificial intelligence and human feedback. Improve this profile .
A mystery illness found in a remote part of Congo has been officially identified as a severe form of malaria, which has sickened nearly 600 people and killed 143.
By: Julia Martin-Ortega, Joshua Cohen, Ruth Bookbinder
To combat climate change and help nature to recover, a lot more investment is urgently needed. The UN’s State of Finance for Nature report claims that if
Oldery man blowing out birthday candles. getty The latest Centers for Disease Control and Prevention report on mortality in the
A polarized country isn’t a recipe for positive change regarding the healthcare sector. Money will still be made, but this won’t necessarily benefit public health.
Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug spending. But thus far, the data don’t show this.
By: Joshua P. Cohen
December 2022, Berlin: Father Ziyad Salem cared for his eight-and-a-half-month-old son Omran Salem, ... [+] who was in the intensive care unit of the pediatric clinic at St.
The most favored nation model would peg the prices of certain prescription drugs paid for in the ... [+] U.S. Medicare program to the lowest prices among peer nations.
Marshmallow Peeps candy used to contain the dye Red No. 3. The company removed Red 3 from the ... [+] product in 2024.
By: Joshua P. Cohen
Medicare announced on January 17, 2025, the next set of 15 prescription drugs that are due for price ... [+] negotiations with pharmaceutical manufacturers this year.
By: Joshua P. Cohen
As Lina Khan, chair of the Federal Trade Commission, ends her tenure this week the FTC posted a second report in six months critical of pharmacy benefit managers.
(833) 317-6278 
